Australia’s first medical cannabis course, designed for health care practitioners, by health care practitioners.
Written & Presented by Dr David Caldicott
Join us for the world premiere of the feature film ‘High as Mike’. Mike has a brain tumour that will eventually rob him of his sight. In this film Mike goes on a cycling road trip to explore the stagnation of medical cannabis prescription in Australia.
A chance to network, meet hosts and keynote speakers. Exciting announcements still to come!
Dr. MacCallum is a clinical instructor in the dept of Medicine at UBC and the medical director at Greenleaf Medical Clinic, a cannabis clinic, using Health Canada approved cannabis.
Dr Towpik has been a General Practitioner in Australia since 1993 and an advocate of medicinal cannabis since the law was amended and cannabis was legalised for medicinal use. Since then she has been studying the therapeutic properties of cannabis, how it works in the human body and the potential applications in General Practice, especially in the management of chronic debilitating pain.
In 2016, Dr Towpik founded MediHuanna, an organisation that provides science-based medicinal cannabis education for Health Professionals. Dr Towpik sees cannabis as a therapeutic agent that has huge potential in General Practice. Her goal is to change the stigma of cannabis through education, enabling it to be seen as an important medicine that should be integrated into modern medicine.
Principal Investigator, Technion Israel Institute of Technology, Laboratory of Cancer Biology and Cannabinoid Research…
Principal Investigator, Technion Israel Institute of Technology, Laboratory of Cancer Biology and Cannabinoid Research
David (Dedi) Meiri, PhD, is an Assistant Professor at the Faculty of Biology at the Technion Israel Institute of Technology and a member of the Technion Integrated Cancer Center (TICC). Dr. Meiri’s scientific background is highly diverse. He holds a M.Sc. in biochemistry and a Ph.D. in plant biotechnology from Tel Aviv University. Dr. Meiri conducted his post-doctoral fellowship at the Ontario Cancer Institute where he focused on the role of the GEF-H1 protein in tumor invasion and metastasis. During his post-doctoral studies, he expanded his knowledge in human biology and cancer pathogenesis and succeeded within a very short time frame to receive worldwide recognition as an expert in the fields of G-protein coupled receptors (GPCRs) and small GTPases. Upon completion of his post-doctoral fellowship, Dr. Meiri took a position at the Technion Israel Institute of Technology, where he heads the “Laboratory of Cancer Biology and Cannabinoid Research”.
Presently, his lab investigates the therapeutic potential of phytocannabinoids, the unique active compounds of the Cannabis sativa plant. On top of other research being conducted in the lab, the main focus of his research is to determine the antitumor effects of cannabinoids, including the anti-metastatic and pro-apoptotic effects of phytocannabinoids.
In addition to the laboratory cannabis research performed on-site, Dr. Meiri collaborates with cannabis growers, clinicians, major manufacturers and distributors of medical cannabis for the purpose of revolutionizing cannabis treatment. He is operating the “Cannabis Database Project” and his lab is currently involved in eight clinical trials covering diverse aspects of cannabis treatment such as colon disease, pain prevention, cancer treatment and epilepsy.
Dr. Meiri is also highly involved in governmental regulations and is a residing member in several Israeli Ministry of Health committees which seek to advance the fundamental understanding of optimal cannabis usage and minimization of adverse side effects.
In 2018 Graham opened the first medical cannabis service in Aotearoa NZ. Cannabis Care Clinic is in Henderson, Auckland providing specialist consultations for legal medicinal cannabis prescriptions…
MB ChB, Dip Obs, PGDip Med Sc (Addiction), FRNZCGP, FAChAM
In 2018 Graham opened the first medical cannabis service in Aotearoa NZ. Cannabis Care Clinic is in Henderson, Auckland providing specialist consultations for legal medicinal cannabis prescriptions. Problems addressed include chronic pain, cancer symptoms, anxiety, chronic insomnia and neurological conditions. Most patients have experienced little benefit or adverse effects from conventional treatment or have been told there are no further treatments. Many report that medicinal cannabis offers symptom relief, improved quality of life and most importantly, restores hope.
His part time general practice experience dates from 1983. Much of this work involves assessing and managing addictions and/or chronic pain. He is a FRNZCGP.
Graham completed his Fellowship of the Australasian Chapter of Addiction Medicine (FAChAM) in 2008. As an Addiction Specialist he manages problems such as alcohol and drug withdrawal, opioid substitution treatment, medication for chronic pain and he writes addiction assessments.
Donald I. Abrams, MD. is the past chief of the Hematology-Oncology Division at San Francisco General Hospital and a Professor of Clinical Medicine at the University of California San Francisco…
Donald I. Abrams, MD. is the past chief of the Hematology-Oncology Division at San Francisco General Hospital and a Professor of Clinical Medicine at the University of California San Francisco.
He has an Integrative Oncology consultation practice at the UCSF Osher Center for Integrative Medicine. He received an A.B. in Molecular Biology from Brown University in 1972 and graduated from the Stanford University School of Medicine in 1977.
After completing an Internal Medicine residency at the Kaiser Foundation Hospital in San Francisco, he became a fellow in Hematology/Oncology at the Cancer Research Institute of the University of California, San Francisco in 1980. He was one the original clinician/investigators to recognize and define many early AIDS-related conditions.
He has long been interested in clinical trials of complementary medicine interventions for HIV/AIDS and cancer, including evaluations of medicinal marijuana. In 1997 he received funding from the National Institute on Drug Abuse to conduct a clinical trial of the short-term safety of cannabinoids in HIV infection. Subsequently he was granted funds by the University of California Center for Medicinal Cannabis Research to conduct a placebo-controlled study of smoked cannabis in patients with painful HIV-related peripheral neuropathy as well as a study evaluating vaporization as a smokeless delivery system for medicinal.
His last NIH-funded trials investigated the possible pharmacokinetic interaction between vaporized cannabis and opioid analgesics in patients with chronic pain and a study of vaporized THC:CBD cannabis in patients with Sickle Cell disease.
He co-authored the chapter on “Cannabinoids and Cancer” in the Oxford University Press Integrative Oncology text that he co-edited with Andrew Weil. He co-edits the NCI PDQ CAM Cannabinoids and Cancer website.
He was a member of the National Academies of Sciences, Engineering and Medicine’s committee that published The Health Effects of Cannabis and Cannabinoids: Current State of Evidence and Recommendations for Research in January 2017.
Jeffrey Hergenrather, MD is a general practitioner specializing in cannabis / cannabinoid medicine since 1999…
Dr Jeffrey Hergenrather, MD is a general practitioner specializing in cannabis / cannabinoid medicine since 1999.
His medical experience includes 26 years in emergency medicine and private general practice that includes the use of cannabis since 1977. He continues in an active consultation practice in northern California with face-to-face, telephone, and on-line consultations for the use of cannabis as medicine.